Investor
Euclidean Capital
2$1.97bn$1.15bn0
Startups backed by Euclidean Capital that were acquired: 2 exits so far, with the buyer, the price where disclosed and every source.
Photo: Unknown / Wikimedia Commons, CC BY 4.0Jazz Pharmaceuticals to buy Actio Biosciences for $820 million upfront
Jazz is paying for one drug: ABS-1230, an oral pill for a rare childhood epilepsy with no approved treatment. Actio's other programs will be spun out into a new company in which Jazz takes a minority stake.
$820m$121mSeries BCorporate
All Euclidean Capital exitsOpen tracker →
Jazz Pharmaceuticals → Actio Biosciences$820m$250m–1bnUCB → Neurona Therapeutics$1.15bn$1bn+